{"title":"缬更昔洛韦治疗早产儿尿毒性和病毒载量","authors":"M. Boesveld, H. L. M. Straaten, M. Hemels","doi":"10.4236/PP.2017.88020","DOIUrl":null,"url":null,"abstract":"Cytomegalovirus (CMV) infection is the most important cause of mental retardation and sensorineural hearing loss. Antiviral treatment with valganciclovir, a relatively new but potential toxic oral drug, is recommended to prevent further hearing deterioration. In this retrospective cohort study we evaluated the relation between the dose of valganciclovir and the reduction of CMV viral load, as well as the toxicity. All neonates with gestational age","PeriodicalId":19875,"journal":{"name":"Pharmacology & Pharmacy","volume":"16 1","pages":"275-282"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Toxicity and Viral Load in Urine during Valganciclovir Therapy in Premature Infants\",\"authors\":\"M. Boesveld, H. L. M. Straaten, M. Hemels\",\"doi\":\"10.4236/PP.2017.88020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cytomegalovirus (CMV) infection is the most important cause of mental retardation and sensorineural hearing loss. Antiviral treatment with valganciclovir, a relatively new but potential toxic oral drug, is recommended to prevent further hearing deterioration. In this retrospective cohort study we evaluated the relation between the dose of valganciclovir and the reduction of CMV viral load, as well as the toxicity. All neonates with gestational age\",\"PeriodicalId\":19875,\"journal\":{\"name\":\"Pharmacology & Pharmacy\",\"volume\":\"16 1\",\"pages\":\"275-282\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacology & Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4236/PP.2017.88020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/PP.2017.88020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Toxicity and Viral Load in Urine during Valganciclovir Therapy in Premature Infants
Cytomegalovirus (CMV) infection is the most important cause of mental retardation and sensorineural hearing loss. Antiviral treatment with valganciclovir, a relatively new but potential toxic oral drug, is recommended to prevent further hearing deterioration. In this retrospective cohort study we evaluated the relation between the dose of valganciclovir and the reduction of CMV viral load, as well as the toxicity. All neonates with gestational age
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
